Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2017, Article ID 1049023, 21 pages
https://doi.org/10.1155/2017/1049023
Research Article

The Differential Contribution of the Innate Immune System to a Good Pathological Response in the Breast and Axillary Lymph Nodes Induced by Neoadjuvant Chemotherapy in Women with Large and Locally Advanced Breast Cancers

1Division of Gastrointestinal Surgery, Nottingham Digestive Diseases Centre, Faculty of Medicine and Health Sciences, University of Nottingham, E. Floor West Block, Queen’s Medical Centre, Derby Road, Nottingham NG7 2UH, UK
2Research & Development Department, Lincoln Breast Unit, Lincoln County Hospital, Greetwell Road, Lincoln LN2 5QY, UK
3Department of Pathology, Path Links, Lincoln County Hospital, Greetwell Road, Lincoln LN2 5QY, UK
4Academic Department of Pathology, Faculty of Medicine and Health Sciences, University of Nottingham, A Floor West Block, Queen’s Medical Centre, Derby Road, Nottingham NG7 2UH, UK
5Department of Surgery, Phramongkutklao Hospital and College of Medicine, 315 Rajavithi Road, Bangkok 10400, Thailand

Correspondence should be addressed to Viriya Kaewkangsadan; ku.oc.oohay@nadasgnakweak

Received 19 April 2017; Accepted 25 July 2017; Published 23 August 2017

Academic Editor: Douglas C. Hooper

Copyright © 2017 Viriya Kaewkangsadan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Aloysius, L. Walker, and O. Eremin, “Cancer and the immune response Ch 4,” Essential Immunology for Surgeons, OUP, Oxford, 2011. View at Google Scholar
  2. W. H. Fridman, J. Galon, F. Pages, E. Tartour, C. Sautes-Fridman, and G. Kroemer, “Prognostic and predictive impact of intra- and peritumoral immune infiltrates,” Cancer Research, vol. 71, no. 17, pp. 5601–5605, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Galon, H. K. Angell, D. Bedognetti, and F. M. Marincola, “The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures,” Immunity, vol. 39, no. 1, pp. 11–26, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. M. W. Teng, S. F. Ngiow, A. Ribas, and M. J. Smyth, “Classifying cancers based on T-cell infiltration and PD-L1,” Cancer Research, vol. 75, no. 11, pp. 2139–2145, 2015. View at Publisher · View at Google Scholar · View at Scopus
  5. L. Zhang, J. R. Conejo-Garcia, D. Katsaros et al., “Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer,” The New England Journal of Medicine, vol. 348, no. 3, pp. 203–213, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. F. Pages, A. Berger, M. Camus et al., “Effector memory T cells, early metastasis, and survival in colorectal cancer,” The New England Journal of Medicine, vol. 353, no. 25, pp. 2654–2666, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. W. H. Fridman, F. Pages, C. Sautes-Fridman, and J. Galon, “The immune contexture in human tumours: impact on clinical outcome,” Nature Reviews Cancer, vol. 12, no. 4, pp. 298–306, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. H. Angell and J. Galon, “From the immune contexture to the immunoscore: the role of prognostic and predictive immune markers in cancer,” Current Opinion in Immunology, vol. 25, no. 2, pp. 261–267, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Denkert, S. Loibl, A. Noske et al., “Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol. 28, no. 1, pp. 105–113, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. R. Yamaguchi, M. Tanaka, A. Yano et al., “Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer,” Human Pathology, vol. 43, no. 10, pp. 1688–1694, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Ono, H. Tsuda, C. Shimizu et al., “Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer,” Breast Cancer Research and Treatment, vol. 132, no. 3, pp. 793–805, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. M. V. Dieci, C. Criscitiello, A. Goubar et al., “Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study,” Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO, vol. 25, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. V. Kaewkangsadan, C. Verma, J. M. Eremin, G. Cowley, M. Ilyas, and O. Eremin, “Crucial contributions by T lymphocytes (effector, regulatory, and checkpoint inhibitor) and cytokines (TH1, TH2, and TH17) to a pathological complete response induced by neoadjuvant chemotherapy in women with breast cancer,” Journal of Immunology Research, vol. 2016, Article ID 4757405, 25 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Ladoire, G. Mignot, S. Dabakuyo et al., “In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival,” The Journal of Pathology, vol. 224, no. 3, pp. 389–400, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. F. Liu, Y. Li, M. Ren et al., “Peritumoral FOXP3(+) regulatory T cell is sensitive to chemotherapy while intratumoral FOXP3(+) regulatory T cell is prognostic predictor of breast cancer patients,” Breast Cancer Research and Treatment, vol. 135, no. 2, pp. 459–467, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. A. N. Seo, H. J. Lee, E. J. Kim et al., “Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer,” British Journal of Cancer, vol. 109, no. 10, pp. 2705–2713, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. E. Garcia-Martinez, G. L. Gil, A. C. Benito et al., “Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer,” Breast Cancer Research, vol. 16, no. 6, p. 488, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. R. J. Steele, M. Brown, and O. Eremin, “Characterisation of macrophages infiltrating human mammary carcinomas,” British Journal of Cancer, vol. 51, no. 1, pp. 135–138, 1985. View at Google Scholar
  19. J. W. Pollard, “Macrophages define the invasive microenvironment in breast cancer,” Journal of Leukocyte Biology, vol. 84, no. 3, pp. 623–630, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. R. D. Leek, C. E. Lewis, R. Whitehouse, M. Greenall, J. Clarke, and A. L. Harris, “Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma,” Cancer Research, vol. 56, no. 20, pp. 4625–4629, 1996. View at Google Scholar
  21. V. Goede, L. Brogelli, M. Ziche, and H. G. Augustin, “Induction of inflammatory angiogenesis by monocyte chemoattractant protein-1,” International Journal of Cancer Journal International du Cancer, vol. 82, no. 5, pp. 765–770, 1999. View at Google Scholar
  22. L. Bingle, N. J. Brown, and C. E. Lewis, “The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies,” The Journal of Pathology, vol. 196, no. 3, pp. 254–265, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Tsutsui, K. Yasuda, K. Suzuki, K. Tahara, H. Higashi, and S. Era, “Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density,” Oncology Reports, vol. 14, no. 2, pp. 425–431, 2005. View at Google Scholar
  24. S. D. Heys, K. N. Stewart, E. J. McKenzie et al., “Characterisation of tumour-infiltrating macrophages: impact on response and survival in patients receiving primary chemotherapy for breast cancer,” Breast Cancer Research and Treatment, vol. 135, no. 2, pp. 539–548, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. C. T. Pham, “Neutrophil serine proteases: specific regulators of inflammation,” Nature Reviews Immunology, vol. 6, no. 7, pp. 541–550, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. C. A. Dumitru, K. Moses, S. Trellakis, S. Lang, and S. Brandau, “Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology,” Cancer Immunology, Immunotherapy, vol. 61, no. 8, pp. 1155–1167, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. E. Di Carlo, G. Forni, P. Lollini, M. P. Colombo, A. Modesti, and P. Musiani, “The intriguing role of polymorphonuclear neutrophils in antitumor reactions,” Blood, vol. 97, no. 2, pp. 339–345, 2001. View at Google Scholar
  28. A. M. Houghton, “The paradox of tumor-associated neutrophils: fueling tumor growth with cytotoxic substances,” Cell Cycle, vol. 9, no. 9, pp. 1732–1737, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Jablonska, S. Leschner, K. Westphal, S. Lienenklaus, and S. Weiss, “Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model,” The Journal of Clinical Investigation, vol. 120, no. 4, pp. 1151–1164, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Bellocq, M. Antoine, A. Flahault et al., “Neutrophil alveolitis in bronchioloalveolar carcinoma: induction by tumor-derived interleukin-8 and relation to clinical outcome,” The American Journal of Pathology, vol. 152, no. 1, pp. 83–92, 1998. View at Google Scholar
  31. H. K. Jensen, F. Donskov, N. Marcussen, M. Nordsmark, F. Lundbeck, and H. von der Maase, “Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol. 27, no. 28, pp. 4709–4717, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. Y. W. Li, S. J. Qiu, J. Fan et al., “Intratumoral neutrophils: a poor prognostic factor for hepatocellular carcinoma following resection,” Journal of Hepatology, vol. 54, no. 3, pp. 497–505, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Ilie, V. Hofman, C. Ortholan et al., “Predictive clinical outcome of the intratumoral CD66b-positive neutrophil-to-CD8-positive T-cell ratio in patients with resectable nonsmall cell lung cancer,” Cancer, vol. 118, no. 6, pp. 1726–1737, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. J. Idoyaga and R. M. Steinman, “SnapShot: dendritic cells,” Cell, vol. 146, no. 4, p. 660.e2, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. T. S. Mathan, C. G. Figdor, and S. I. Buschow, “Human plasmacytoid dendritic cells: from molecules to intercellular communication network,” Frontiers in Immunology, vol. 4, p. 372, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. J. Banchereau and R. M. Steinman, “Dendritic cells and the control of immunity,” Nature, vol. 392, no. 6673, pp. 245–252, 1998. View at Publisher · View at Google Scholar · View at Scopus
  37. K. Palucka and J. Banchereau, “SnapShot: cancer vaccines,” Cell, vol. 157, no. 2, p. 516.e1, 2014. View at Publisher · View at Google Scholar · View at Scopus
  38. A. J. Tesone, N. Svoronos, M. J. Allegrezza, and J. R. Conejo-Garcia, “Pathological mobilization and activities of dendritic cells in tumor-bearing hosts: challenges and opportunities for immunotherapy of cancer,” Frontiers in Immunology, vol. 4, p. 435, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Satthaporn and O. Eremin, “Dendritic cells (II): role and therapeutic implications in cancer,” Journal of the Royal College of Surgeons of Edinburgh, vol. 46, no. 3, pp. 159–167, 2001. View at Google Scholar
  40. E. E. Hillenbrand, A. M. Neville, and B. J. Coventry, “Immunohistochemical localization of CD1a-positive putative dendritic cells in human breast tumours,” British Journal of Cancer, vol. 79, no. 5-6, pp. 940–944, 1999. View at Publisher · View at Google Scholar · View at Scopus
  41. B. J. Coventry, P. L. Lee, D. Gibbs, and D. N. Hart, “Dendritic cell density and activation status in human breast cancer—CD1a, CMRF-44, CMRF-56 and CD-83 expression,” British Journal of Cancer, vol. 86, no. 4, pp. 546–551, 2002. View at Publisher · View at Google Scholar · View at Scopus
  42. A. S. Mansfield, P. Heikkila, K. von Smitten, J. Vakkila, and M. Leidenius, “Metastasis to sentinel lymph nodes in breast cancer is associated with maturation arrest of dendritic cells and poor co-localization of dendritic cells and CD8+ T cells,” Virchows Archiv: An International Journal of Pathology, vol. 459, no. 4, pp. 391–398, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. S. Satthaporn, A. Robins, W. Vassanasiri et al., “Dendritic cells are dysfunctional in patients with operable breast cancer,” Cancer Immunology, Immunotherapy, vol. 53, no. 6, pp. 510–518, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. B. J. Coventry and J. Morton, “CD1a-positive infiltrating-dendritic cell density and 5-year survival from human breast cancer,” British Journal of Cancer, vol. 89, no. 3, pp. 533–538, 2003. View at Publisher · View at Google Scholar · View at Scopus
  45. C. Verma, V. Kaewkangsadan, J. M. Eremin et al., “Natural killer (NK) cell profiles in blood and tumour in women with large and locally advanced breast cancer (LLABC) and their contribution to a pathological complete response (PCR) in the tumour following neoadjuvant chemotherapy (NAC): differential restoration of blood profiles by NAC and surgery,” Journal of Translational Medicine, vol. 13, p. 180, 2015. View at Publisher · View at Google Scholar · View at Scopus
  46. J. Eremin, G. Cowley, L. G. Walker, E. Murray, M. Stovickova, and O. Eremin, “Women with large (≥3 cm) and locally advanced breast cancers (T3, 4, N1, 2, M0) receiving neoadjuvant chemotherapy (NAC: cyclophosphamide, doxorubicin, docetaxel): addition of capecitabine improves 4-year disease-free survival,” SpringerPlus, vol. 4, p. 9, 2015. View at Publisher · View at Google Scholar · View at Scopus
  47. K. N. Ogston, I. D. Miller, S. Payne et al., “A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival,” Breast, vol. 12, no. 5, pp. 320–327, 2003. View at Google Scholar
  48. L. G. Walker, J. M. Eremin, M. M. Aloysius et al., “Effects on quality of life, anti-cancer responses, breast conserving surgery and survival with neoadjuvant docetaxel: a randomised study of sequential weekly versus three-weekly docetaxel following neoadjuvant doxorubicin and cyclophosphamide in women with primary breast cancer,” BMC Cancer, vol. 11, p. 179, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. J. Forssell, A. Oberg, M. L. Henriksson, R. Stenling, A. Jung, and R. Palmqvist, “High macrophage infiltration along the tumor front correlates with improved survival in colon cancer,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, vol. 13, no. 5, pp. 1472–1479, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. Q. Zhou, R. Q. Peng, X. J. Wu et al., “The density of macrophages in the invasive front is inversely correlated to liver metastasis in colon cancer,” Journal of Translational Medicine, vol. 8, p. 13, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. S. Edin, M. L. Wikberg, A. M. Dahlin et al., “The distribution of macrophages with a M1 or M2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer,” PLoS One, vol. 7, no. 10, article e47045, 2012. View at Publisher · View at Google Scholar · View at Scopus
  52. N. Oda, K. Shimazu, Y. Naoi et al., “Intratumoral regulatory T cells as an independent predictive factor for pathological complete response to neoadjuvant paclitaxel followed by 5-FU/epirubicin/cyclophosphamide in breast cancer patients,” Breast Cancer Research and Treatment, vol. 136, no. 1, pp. 107–116, 2012. View at Publisher · View at Google Scholar · View at Scopus
  53. L. Demir, S. Yigit, H. Ellidokuz et al., “Predictive and prognostic factors in locally advanced breast cancer: effect of intratumoral FOXP3+ Tregs,” Clinical & Experimental Metastasis, vol. 30, 2013. View at Publisher · View at Google Scholar · View at Scopus
  54. A. S. Mansfield, P. Heikkila, K. von Smitten, J. Vakkila, and M. Leidenius, “The presence of sinusoidal CD163(+) macrophages in lymph nodes is associated with favorable nodal status in patients with breast cancer,” Virchows Archiv: An International Journal of Pathology, vol. 461, no. 6, pp. 639–646, 2012. View at Publisher · View at Google Scholar · View at Scopus
  55. K. S. McCarty Jr., L. S. Miller, E. B. Cox, J. Konrath, and K. S. McCarty Sr., “Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies,” Archives of Pathology & Laboratory Medicine, vol. 109, no. 8, pp. 716–721, 1985. View at Google Scholar
  56. L. C. Collins, M. L. Botero, and S. J. Schnitt, “Bimodal frequency distribution of estrogen receptor immunohistochemical staining results in breast cancer: an analysis of 825 cases,” American Journal of Clinical Pathology, vol. 123, no. 1, pp. 16–20, 2005. View at Google Scholar
  57. C. Verma, J. M. Eremin, A. Robins et al., “Abnormal T regulatory cells (Tregs: FOXP3+, CTLA-4+), myeloid-derived suppressor cells (MDSCs: monocytic, granulocytic) and polarised T helper cell profiles (Th1, Th2, Th17) in women with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC) and surgery: failure of abolition of abnormal treg profile with treatment and correlation of treg levels with pathological response to NAC,” Journal of Translational Medicine, vol. 11, p. 16, 2013. View at Publisher · View at Google Scholar · View at Scopus
  58. W. Sha, B. Brune, and A. Weigert, “The multi-faceted roles of prostaglandin E2 in cancer-infiltrating mononuclear phagocyte biology,” Immunobiology, vol. 217, no. 12, pp. 1225–1232, 2012. View at Publisher · View at Google Scholar · View at Scopus
  59. C. Murdoch, M. Muthana, S. B. Coffelt, and C. E. Lewis, “The role of myeloid cells in the promotion of tumour angiogenesis,” Nature Reviews Cancer, vol. 8, no. 8, pp. 618–631, 2008. View at Publisher · View at Google Scholar · View at Scopus
  60. A. Mantovani, P. Allavena, A. Sica, and F. Balkwill, “Cancer-related inflammation,” Nature, vol. 454, no. 7203, pp. 436–444, 2008. View at Publisher · View at Google Scholar · View at Scopus
  61. S. K. Moestrup and H. J. Moller, “CD163: a regulated hemoglobin scavenger receptor with a role in the anti-inflammatory response,” Annals of Medicine, vol. 36, no. 5, pp. 347–354, 2004. View at Google Scholar
  62. B. Z. Qian and J. W. Pollard, “Macrophage diversity enhances tumor progression and metastasis,” Cell, vol. 141, no. 1, pp. 39–51, 2010. View at Publisher · View at Google Scholar · View at Scopus
  63. C. Porta, B. Subhra Kumar, P. Larghi, L. Rubino, A. Mancino, and A. Sica, “Tumor promotion by tumor-associated macrophages,” Advances in Molecular Oncology, vol. 604, pp. 67–86, 2007. View at Google Scholar
  64. A. Boissonnas, F. Licata, L. Poupel et al., “CD8+ tumor-infiltrating T cells are trapped in the tumor-dendritic cell network,” Neoplasia, vol. 15, no. 1, pp. 85–94, 2013. View at Google Scholar
  65. R. Noy and J. W. Pollard, “Tumor-associated macrophages: from mechanisms to therapy,” Immunity, vol. 41, no. 1, pp. 49–61, 2014. View at Publisher · View at Google Scholar · View at Scopus
  66. G. von Minckwitz, M. Untch, J. U. Blohmer et al., “Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol. 30, no. 15, pp. 1796–1804, 2012. View at Publisher · View at Google Scholar · View at Scopus
  67. P. Cortazar, L. Zhang, M. Untch et al., “Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis,” Lancet, vol. 384, no. 9938, pp. 164–172, 2014. View at Publisher · View at Google Scholar · View at Scopus
  68. E. H. Lips, L. Mulder, J. J. de Ronde et al., “Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response,” Breast Cancer Research and Treatment, vol. 140, no. 1, pp. 63–71, 2013. View at Publisher · View at Google Scholar · View at Scopus
  69. L. J. Esserman, D. A. Berry, A. DeMichele et al., “Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol. 30, no. 26, pp. 3242–3249, 2012. View at Publisher · View at Google Scholar · View at Scopus
  70. B. S. Rose, E. P. Winer, and H. J. Mamon, “Perils of the pathologic complete response,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol. 34, 2016. View at Publisher · View at Google Scholar · View at Scopus
  71. T. J. Curiel, S. Wei, H. Dong et al., “Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity,” Nature Medicine, vol. 9, no. 5, pp. 562–567, 2003. View at Publisher · View at Google Scholar · View at Scopus
  72. I. Perrot, D. Blanchard, N. Freymond et al., “Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage,” Journal of Immunology, vol. 178, no. 5, pp. 2763–2769, 2007. View at Google Scholar
  73. S. Tsujitani, T. Furukawa, R. Tamada, T. Okamura, K. Yasumoto, and K. Sugimachi, “Langerhans cells and prognosis in patients with gastric carcinoma,” Cancer, vol. 59, no. 3, pp. 501–505, 1987. View at Google Scholar
  74. K. Ambe, M. Mori, and M. Enjoji, “S-100 protein-positive dendritic cells in colorectal adenocarcinomas. Distribution and relation to the clinical prognosis,” Cancer, vol. 63, no. 3, pp. 496–503, 1989. View at Google Scholar
  75. N. A. Zeid and H. K. Muller, “S100 positive dendritic cells in human lung tumors associated with cell differentiation and enhanced survival,” Pathology, vol. 25, no. 4, pp. 338–343, 1993. View at Google Scholar
  76. D. Avigan, “Dendritic cells: development, function and potential use for cancer immunotherapy,” Blood Reviews, vol. 13, no. 1, pp. 51–64, 1999. View at Google Scholar
  77. I. E. Dumitriu, D. R. Dunbar, S. E. Howie, T. Sethi, and C. D. Gregory, “Human dendritic cells produce TGF-beta 1 under the influence of lung carcinoma cells and prime the differentiation of CD4+CD25+Foxp3+ regulatory T cells,” Journal of Immunology, vol. 182, no. 5, pp. 2795–2807, 2009. View at Publisher · View at Google Scholar · View at Scopus
  78. A. D. Garg, D. V. Krysko, T. Verfaillie et al., “A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death,” The EMBO Journal, vol. 31, no. 5, pp. 1062–1079, 2012. View at Publisher · View at Google Scholar · View at Scopus
  79. G. Kroemer, L. Galluzzi, O. Kepp, and L. Zitvogel, “Immunogenic cell death in cancer therapy,” Annual Review of Immunology, vol. 31, pp. 51–72, 2013. View at Publisher · View at Google Scholar · View at Scopus
  80. N. Tsavaris, C. Kosmas, M. Vadiaka, P. Kanelopoulos, and D. Boulamatsis, “Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes,” British Journal of Cancer, vol. 87, no. 1, pp. 21–27, 2002. View at Publisher · View at Google Scholar · View at Scopus
  81. F. Ghiringhelli, C. Menard, P. E. Puig et al., “Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients,” Cancer Immunology, Immunotherapy, vol. 56, no. 5, pp. 641–648, 2007. View at Publisher · View at Google Scholar · View at Scopus
  82. J. Y. Park, M. J. Jang, Y. H. Chung et al., “Doxorubicin enhances CD4(+) T-cell immune responses by inducing expression of CD40 ligand and 4-1BB,” International Immunopharmacology, vol. 9, no. 13-14, pp. 1530–1539, 2009. View at Publisher · View at Google Scholar · View at Scopus
  83. C. M. Barbon, M. Yang, G. D. Wands et al., “Consecutive low doses of cyclophosphamide preferentially target Tregs and potentiate T cell responses induced by DNA PLG microparticle immunization,” Cellular Immunology, vol. 262, no. 2, pp. 150–161, 2010. View at Publisher · View at Google Scholar · View at Scopus
  84. M. Aloysius, C. Verma, and O. Eremin, “Therapy and host defences Ch 7,” Essential Immunology for Surgeons, OUP, Oxford, 2011. View at Google Scholar
  85. L. Menger, E. Vacchelli, S. Adjemian et al., “Cardiac glycosides exert anticancer effects by inducing immunogenic cell death,” Science Translational Medicine, vol. 4, no. 143, article 143ra99, 2012. View at Publisher · View at Google Scholar · View at Scopus
  86. N. Casares, M. O. Pequignot, A. Tesniere et al., “Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death,” The Journal of Experimental Medicine, vol. 202, no. 12, pp. 1691–1701, 2005. View at Publisher · View at Google Scholar · View at Scopus
  87. S. R. Mattarollo, S. Loi, H. Duret, Y. Ma, L. Zitvogel, and M. J. Smyth, “Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors,” Cancer Research, vol. 71, no. 14, pp. 4809–4820, 2011. View at Publisher · View at Google Scholar · View at Scopus
  88. J. Vincent, G. Mignot, F. Chalmin et al., “5-fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity,” Cancer Research, vol. 70, no. 8, pp. 3052–3061, 2010. View at Publisher · View at Google Scholar · View at Scopus
  89. G. M. Weir, R. S. Liwski, and M. Mansour, “Immune modulation by chemotherapy or immunotherapy to enhance cancer vaccines,” Cancer, vol. 3, no. 3, pp. 3114–3142, 2011. View at Publisher · View at Google Scholar · View at Scopus
  90. A. W. Tong, B. Seamour, J. M. Lawson et al., “Cellular immune profile of patients with advanced cancer before and after taxane treatment,” American Journal of Clinical Oncology, vol. 23, no. 5, pp. 463–472, 2000. View at Google Scholar